NEW YORK ( TheStreet) -- CHANGE IN RATINGS
was upgraded to buy at TheStreet Ratings.
was downgraded to hold at TheStreet Ratings.
(INTC - Get Report)
earnings estimates were reduced at UBS. The lowered outlook reflects a sub-seasonal PC client trend, said UBS. Price target remains $22.50.
price target was increased to $105 by JPMorgan. Palbociclib (palbo, or PD-991), a breast cancer drug, is now included in the valuation, said JPMorgan.
(VRSN - Get Report)
price target was increased to $50 at Citigroup. The new price target reflects the likelihood of a significant debt raise, said Citigroup.
price target increased at Citi. The initial mid-term outlook provided at Z's fist analyst day led to a new price target of $70, said Citigroup.
estimates and price target cut at MKM. RHT earnings estimates through 2014 were reduced on management guidance, said MKM Partners. The new price target is $53.
price target was reduced to $29 at Benchmark. Lower fiscal 2Q guidance reflects uncertainty related to its ongoing business transformation, said Benchmark.